MGTX Stock Analysis: MeiraGTx Holdings | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 844m USD | 12M Return: 10.9% | KYG596651029 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 5.90M
Qual. Beats: 0
Rev. Trend: 90.8%
Qual. Beats: 1
Warnings
Tailwinds
No distinct edge detected
Seasonality 8.4 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
MeiraGTx Holdings plc is a clinical-stage biotechnology company developing gene therapies for serious diseases. Founded in 2015 and headquartered in New York, the company uses adeno-associated virus (AAV) vectors to deliver genetic treatments, a common approach in the gene therapy field where clinical-stage firms typically rely on partnerships and capital markets for funding before commercial revenue begins.
The companys pipeline spans multiple therapeutic areas, with a primary focus on ocular diseases. Clinical-stage programs include AAV-GAD for Parkinsons disease, AAV-RPE65 for retinal dystrophy, and AAV-CNGB3 and AAV-CNGA3 for achromatopsia. Additional clinical work targets radiation-induced xerostomia and Sjogrens syndrome, while preclinical programs address conditions such as Bardet-Biedl syndrome, Leber congenital amaurosis, amyotrophic lateral sclerosis, Alzheimers disease, and age-related macular degeneration.
Beyond ocular and neurological programs, MeiraGTx operates a riboswitch platform for metabolic peptide delivery and develops cell therapies for oncology, autoimmune disease, and intractable pain. The company has commercial collaborations with Johnson & Johnson Innovative Medicine for inherited retinal disease gene therapies and with Hologen Limited for central nervous system gene therapies, including treatments for Parkinsons disease and genetic obesity disorders.
- Phase 2 gene therapy readouts for Parkinsons and retinal diseases
- Johnson & Johnson collaboration milestones boost partnership revenue
- Rising cash burn raises dilution risk from equity offerings
| Net Income: 79.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA 68.42 > 1.0 |
| NWC/Revenue: 40.31% < 20% (prev -16.75%; Δ 57.07% < -1%) |
| CFO/TA 0.03 > 3% & CFO 13.7m > Net Income 79.0m |
| Net Debt (-18.5m) to EBITDA (262.4m): -0.07 < 3 |
| Current Ratio: 3.76 > 1.5 & < 3 |
| Outstanding Shares: last quarter (93.8m) vs 12m ago 16.40% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 133.6% > 50% (prev 19.08%; Δ 114.5% > 0%) |
| Interest Coverage Ratio: 20.06 > 6 (EBIT TTM 250.2m / Interest Expense TTM 12.5m) |
| A: 0.40 (Total Current Assets 218.3m - Total Current Liabilities 58.1m) / Total Assets 396.4m |
| B: -1.77 (Retained Earnings -701.8m / Total Assets 396.4m) |
| C: 0.84 (EBIT TTM 250.2m / Avg Total Assets 297.6m) |
| D: 1.19 (Book Value of Equity 215.6m / Total Liabilities 180.7m) |
| Altman-Z'' = 3.78 = AA |
| DSRI: 0.62 (Receivables 44.3m/6.79m, Revenue 397.5m/37.9m) |
| GMI: 0.27 (GM 26.56% / 97.19%) |
| AQI: 2.03 (AQ_t 0.11 / AQ_t-1 0.05) |
| SGI: 10.48 (Revenue 397.5m / 37.9m) |
| TATA: 0.16 (NI 79.0m - CFO 13.7m) / TA 396.4m) |
| Beneish M = 3.43 (Cap -4..+1) = D |
As of November 17, 2026, the stock is trading at USD 8.74 with a total of 706,057 shares traded. Over the past week, the price has changed by -7.90%, over one month by -5.82%, over three months by -36.53% and over the past year by +10.91%.
Current recommended Stop Loss: 8.00 (which is 8.5% or 1.3 ATR below the current price).
MeiraGTx Holdings has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy MGTX.
- StrongBuy: 5
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 27.8 | 217.5% |
P/E Trailing = 10.1034
P/E Forward = 64.1026
P/S = 2.1238
P/B = 4.3105
Revenue TTM = 397.5m USD
EBIT TTM = 250.2m USD
EBITDA TTM = 262.4m USD
Long Term Debt = 100.0m USD (from longTermDebt, last quarter)
Short Term Debt = 2.30m USD (from shortTermDebt, last quarter)
Debt = 124.6m USD (from shortLongTermDebtTotal, last quarter) + Leases 12.3m
Net Debt = -18.5m USD (calculated: Debt 124.6m - CCE 143.2m)
Enterprise Value = 825.7m USD (844.2m + Debt 124.6m - CCE 143.2m)
Interest Coverage Ratio = 20.06 (Ebit TTM 250.2m / Interest Expense TTM 12.5m)
EV/FCF = 208.0x (Enterprise Value 825.7m / FCF TTM 3.97m)
FCF Yield = 0.48% (FCF TTM 3.97m / Enterprise Value 825.7m)
FCF Margin = 1.00% (FCF TTM 3.97m / Revenue TTM 397.5m)
Net Margin = 19.87% (Net Income TTM 79.0m / Revenue TTM 397.5m)
Gross Margin = unknown ((Revenue TTM 397.5m - Cost of Revenue TTM 11.2m) / Revenue TTM)
Tobins Q-Ratio = 2.08 (Enterprise Value 825.7m / Total Assets 396.4m)
Interest Expense / Debt = 10.01% (Interest Expense 12.5m / Debt 124.6m)
Taxrate = 1.45% (2.36m / 163.0m)
NOPAT = 246.6m (EBIT 250.2m * (1 - 1.45%))
Current Ratio = 3.76 (Total Current Assets 218.3m / Total Current Liabilities 58.1m)
Debt / Equity = 0.58 (Debt 124.6m / totalStockholderEquity, last quarter 215.6m)
Debt / EBITDA = -0.07 (Net Debt -18.5m / EBITDA 262.4m)
Debt / FCF = -4.67 (Net Debt -18.5m / FCF TTM 3.97m)
Total Stockholder Equity = 27.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 26.54% (Net Income 79.0m / Total Assets 396.4m)
RoE = 284.4% (Net Income TTM 79.0m / Total Stockholder Equity 27.8m)
RoCE = 195.9% (EBIT 250.2m / Capital Employed (Equity 27.8m + L.T.Debt 100.0m))
RoIC = 76.88% (NOPAT 246.6m / Invested Capital 320.8m)
WACC = 10.50% (E(844.2m)/V(968.9m) * Re(10.59%) + D(124.6m)/V(968.9m) * Rd(10.01%) * (1-Tc(0.01)))
Discount Rate = 10.59% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 93.77 | Cagr: 18.47%
[DCF] Terminal Value 68.30% ; FCFF base≈3.97m ; Y1≈3.99m ; Y5≈4.22m
[DCF] Fair Price = 0.69 (EV 48.1m - Net Debt -18.5m = Equity 66.6m / Shares 96.0m; r=10.50% [WACC]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.09 | # QB: 0
Revenue Correlation: 90.79 | Revenue CAGR: 221.4% | SUE: 4.0 | # QB: 1
EPS current Year (2026-12-31): EPS=0.51 | Chg30d=+0.00% | Revisions=+40% | GrowthEPS=+135.9% | GrowthRev=+314.2%
EPS next Year (2027-12-31): EPS=-1.52 | Chg30d=-9.71% | Revisions=+25% | GrowthEPS=-399.0% | GrowthRev=-80.2%
[Analyst] Revisions Ratio: +50% (up=3, down=0)